Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 217,797,366 papers from all fields of science
Search
Sign In
Create Free Account
onabotulinumtoxinA 200 UNT Injection [Botox]
Known as:
Botox 200 UNT Injection
, botulinum toxin type A 200 [USP'U] INTRADERMAL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [BOTOX]
, Botox 200 UNT/ML Injectable Solution
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
7 relations
Albumin Human, USP
Botox
Botulinum Toxin Type A
Injection
Expand
Broader (1)
onabotulinumtoxinA 200 UNT Injection
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Sphincter of Oddi Function and Risk Factors for Dysfunction
E. Afghani
,
S. Lo
,
P. Covington
,
B. Cash
,
S. Pandol
Frontiers in Nutrition
2017
Corpus ID: 2559218
The sphincter of Oddi (SO) is a smooth muscle valve regulating the flow of biliary and pancreatic secretions into the duodenum…
Expand
Highly Cited
2016
Highly Cited
2016
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
A. Negro
,
M. Curto
,
L. Lionetto
,
P. Martelletti
The Journal of Headache and Pain
2016
Corpus ID: 22992635
BackgroundThe efficacy and safety of OnabotulinumtoxinA (BOTOX®) in adults with chronic migraine (CM) were demonstrated in the…
Expand
Review
2016
Review
2016
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
F. Scaglione
Toxins
2016
Corpus ID: 10537560
Botulinum neurotoxin has revolutionized the treatment of spasticity and is now administered worldwide. There are currently three…
Expand
Review
2014
Review
2014
Outcome After Anal Intrasphincteric Botox Injection in Children With Surgically Treated Hirschsprung Disease
I. Han-Geurts
,
V. Hendrix
,
I. de Blaauw
,
M. Wijnen
,
E. van Heurn
Journal of Pediatric Gastroenterology and…
2014
Corpus ID: 22729118
Objectives: A nonrelaxing internal anal sphincter is present in a relatively large proportion of children with surgically treated…
Expand
Highly Cited
2010
Highly Cited
2010
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial.
R. Dmochowski
,
C. Chapple
,
+6 authors
C. Haag‐Molkenteller
Journal of Urology
2010
Corpus ID: 39876537
Highly Cited
2010
Highly Cited
2010
Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®
J. Frevert
Drugs in R&D
2010
Corpus ID: 15873603
AbstractBackground: Botulinum neurotoxin type A (BoNT/A) is the active substance in preparations used for the highly effective…
Expand
Highly Cited
2009
Highly Cited
2009
Comparative study of Botox® injection treatment for upper eyelid retraction with 6-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stage
P. G. Costa
,
F. P. Saraiva
,
I. C. Pereira
,
Mário Luiz Ribeiro Monteiro
,
S. Matayoshi
Eye
2009
Corpus ID: 21999050
AimTo compare morphometric data of the eyelid fissure and the levator muscle function (LF) before and up to 6 months after…
Expand
Review
2008
Review
2008
Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity
Raymond L. Rosales
,
A. S. Chua-Yap
Journal of neural transmission
2008
Corpus ID: 30836869
SummaryBackground. Botulinum toxin type A (BoNTA) has been suggested as an effective anti-spastic drug. In this article, we…
Expand
Highly Cited
2006
Highly Cited
2006
Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm
P. Roggenkämper
,
W. Jost
,
K. Bihari
,
G. Comes
,
S. Grafe
,
For the ProREAL study team
Journal of neural transmission
2006
Corpus ID: 8265918
Summary.NT 201 is a new development of Botulinum Toxin Type A free of complexing proteins. In this double-blind Phase III trial…
Expand
Highly Cited
1999
Highly Cited
1999
Medium‐term response characterisation and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy
R. Boyd
,
J. Graham
,
G. Nattrass
,
H. Graham
1999
Corpus ID: 71906016
We prospectively studied the medium‐term effects of botulinum toxin type A (BTX‐A) treatment in 197 children with cerebral palsy…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE